Ann: FDA Strategy and Regulatory Update, page-207

Constant dumping into 1.1c. The next week is a very telling week for the company and I don’t mean just in regards to FDA. The milestones set are targeting 2 signed agreements and at this stage we have none. There has been a lot of talk regarding compass and others show heightened interest in ilumen but the company is yet to execute a signed agreement.
FDA being a delayed a little is not a big concern in my opinion, the main concern is the company being able to execute a commercial contract for the non regulated part of the business, ie ilumen.